Physician

Chad Michael Ronholm, M.D.

According to 2025 Medicare claims, Chad Ronholm, M.D. (NPI: 1306027909) practices rheumatology in the St. Louis, MO-IL market, with the plurality of this provider's patient population coming from St. Louis, MO. This provider's primary affiliated billing organization is CLAYTON MEDICAL ASSOCIATES, P.C. (NPI: 1891774329; TIN: 43-1907813) and primary practice location at 63119-3845. Ronholm is affiliated with the IRCCO (ACO ID: A2619), SSM IL ACO, LLC (ACO ID: A4832), SBL accountable care organization (ACO ID: A5147), and Caravan Health ACO 50 LLC (ACO ID: A5160), participating under the MSSP model.

Ronholm's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 532 traditional Medicare patients, billed 234,607 HCPCS/CPT codes, and received $3,074,711 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 2,370 prescription claims across 479 beneficiaries totaling $1,141,040 in drug costs, led by Humira(Cf) Pen (Adalimumab). 2019 DME data shows 11 claims. Open Payments data shows 216 records totaling $56,094. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $97,049 to $3,074,711. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	281	10,213	$97,049
2016	294	5,631	$68,095
2017	226	10,367	$230,800
2018	200	22,106	$344,540
2019	221	30,578	$523,691
2020	214	38,497	$989,553
2021	255	43,401	$1,155,580
2022	260	40,399	$535,407
2023	302	72,079	$787,879
2024	532	234,607	$3,074,711

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	352	3,289	$688,512
2016	407	3,218	$1,120,216
2017	310	2,510	$1,017,888
2018	265	2,760	$1,205,669
2019	265	1,934	$1,264,760
2020	270	1,792	$1,173,212
2021	302	1,780	$1,146,793
2022	265	1,663	$1,084,909
2023	338	1,938	$1,408,776
2024	479	2,370	$1,141,040

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	11	$723
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	141	943	$95
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	452	1,220	$92
76881	Complete ultrasound scan of joint	99	103	$40
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	88	90	$13
J7050	Infusion, normal saline solution, 250 cc	139	922	$0

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Humira(Cf) Pen	Adalimumab	35	1,036	$280,062
Rinvoq	Upadacitinib	26	780	$162,590
Orencia Clickject	Abatacept	19	532	$122,704
Humira Pen	Adalimumab	12	364	$105,801
Savella	Milnacipran Hcl	15	900	$14,630

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	212	$4,063	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	4	$52,032	Eli Lilly and Company
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Chad Michael Ronholm, M.D.?

Tedicare shows public-source Medicare data for Chad Michael Ronholm, M.D. (NPI 1306027909), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Chad Michael Ronholm, M.D. have ACO affiliation data?

Chad Michael Ronholm, M.D. is shown with ACO affiliation data for IRCCO (MSSP, ACO ID A2619), SSM IL ACO, LLC (MSSP, ACO ID A4832), SBL accountable care organization (MSSP, ACO ID A5147), and Caravan Health ACO 50 LLC (MSSP, ACO ID A5160).

What billing organization is linked to Chad Michael Ronholm, M.D.?

Chad Michael Ronholm, M.D. is linked to CLAYTON MEDICAL ASSOCIATES, P.C. (billing NPI 1891774329) in the available physician profile data.

Does Chad Michael Ronholm, M.D. have Open Payments data?

Chad Michael Ronholm, M.D. has 216 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.